ICAM-1 expression by lung cancer cell lines: effects of upregulation by cytokines on the interaction with LAK cells

Melis, Marcello; Spatafora, Mario; Melodia, A.; Pace, Elisabetta; Gjomarkaj, Mark; Merendino, Anna Maria; Bonsignore, G

doi:10.1183/09031936.96.09091831

Cited by 29 publications

(22 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For example, adhesion molecules are implicated in the cellto-cell contact between tumour cells and LAK or NK cells. Thus, a recent report demonstrated that ICAM-1 was expressed spontaneously by NSCLC cell lines and by IFN-γ-stimulated SCLC cell lines [172]. Together with other cell adhesion molecules, ICAM-1 could facilitate the binding of tumour cells to LAK cells.…”

Section: Adhesion Moleculesmentioning

confidence: 99%

Pulmonary perspective: immunology in diagnosis and treatment of lung cancer

Weynants

Marchandise²,

Sibille³

1997

Eur Respir J

View full text Add to dashboard Cite

show abstract

Section: Adhesion Moleculesmentioning

confidence: 99%

Pulmonary perspective: immunology in diagnosis and treatment of lung cancer

Weynants

Marchandise²,

Sibille³

1997

Eur Respir J

View full text Add to dashboard Cite

show abstract

“…In the past few years several new targets have been identified for NSC lung cancer, most notably EGFR and VEGF, and it is hoped that they will translate to improved treatment outcomes. [49][50][51] Since CD54 is also up-regulated on a majority of NSC lung tumor cell lines investigated in this and other studies, 21,22 it might represent another important therapeutic target. When administered to SCID/NSC lung tumor mice, UV3 slowed the growth of palpable tumors, both alone and in combination with chemotherapy.…”

Section: Discussionmentioning

confidence: 99%

“…Due to its demonstrated anti-tumor activity, UV3 has been chimerized (cUV3) to reduce its immunogenicity in humans. 17 Since CD54 expression is up-regulated in many different types of cancer cells, [18][19][20][21][22] we hypothesized that UV3 would have activity against other CD54 1 tumors as well. We have now expanded the testing of UV3 to include human breast, prostate, NSC lung, and pancreatic tumor cell lines.…”

mentioning

confidence: 99%

The antitumor activity of an anti‐CD54 antibody in SCID mice xenografted with human breast, prostate, non‐small cell lung, and pancreatic tumor cell lines

Brooks

Coleman

Vitetta

2008

Intl Journal of Cancer

View full text Add to dashboard Cite

We have previously described the development and testing of a monoclonal anti-human CD54 antibody (UV3) in SCID mice xenografted with human multiple myeloma, lymphoma, and melanoma cell lines. In all 3 cases, UV3 was highly effective at slowing the growth of tumors and/or prolonging survival. Since CD54 (ICAM-1) is up-regulated on many different types of cancer cells, we have now investigated the anti-tumor activity of UV3 in several other CD54 1 epithelial tumors. A panel of 16 human breast, prostate, non-small cell (NSC) lung, and pancreatic tumor cell lines was examined for reactivity with UV3, and 13 were positive. A representative CD54 1 cell line from each cancer was grown subcutaneously in SCID mice. Once the tumors were established, UV3 was administered using different dose regimens. UV3 slowed the growth of all 4 tumors, although it was not curative. When UV3 or gemcitabine were administered to SCID mice xenografted with a NSC lung tumor cell line or a pancreatic tumor cell line, UV3 was as effective as the chemotherapy alone. When gemcitabine and UV3 were administered together, the best anti-tumor responses were observed. UV3 has been chimerized (cUV3) and both toxicology studies and clinical trials are planned to assess the safety and activity of cUV3 in patients with one or more of these tumors.

show abstract

“…ICAM-1 is up-regulated on the surface of a variety of lymphomas, pancreatic, bladder and lung carcinomas and/or their local vascular network [99]. A cyclic peptide, cyclo-(1,12)-PenITDGEATDSGC (cLABL), derived from the Idomain of the L subunit of leukocyte function associated antigen-1 LFA-1 integrin has been shown the binding affinity to the D1 domain of ICAM-1 [100].…”

Section: Cell Adhesion Molecule Receptor Targeted Therapymentioning

confidence: 99%

Receptor Mediated Tumor Targeting: An Emerging Approach for Cancer Therapy

Mohanty

Das²,

Kanwar³

et al. 2011

CDD

View full text Add to dashboard Cite

Receptor-mediated tumor targeting has received major attention in the field of cancer drug delivery in the past few years. Receptors, as molecular target has opened new opportunities for cellular or intracellular targeting of drug loaded delivery systems conjugated with targeting moieties i.e. ligand. This receptor mediated targeting of cancer drug through nano carrier systems to cancerous tissue offer protection and improves the pharmacokinetics of various drugs and help to overcome the systemic toxicity and adverse effects that result from the non-selective nature of most current cancer therapeutic agents. The article reviews the scope of receptor mediated targeting of anticancer drug loaded in various nanocarriers and also summarize recent perspective and challenges in the field of nanocarrier-aided drug delivery and drug targeting for cancer therapy.

show abstract

ICAM-1 expression by lung cancer cell lines: effects of upregulation by cytokines on the interaction with LAK cells

Cited by 29 publications

References 23 publications

Pulmonary perspective: immunology in diagnosis and treatment of lung cancer

Pulmonary perspective: immunology in diagnosis and treatment of lung cancer

The antitumor activity of an anti‐CD54 antibody in SCID mice xenografted with human breast, prostate, non‐small cell lung, and pancreatic tumor cell lines

Receptor Mediated Tumor Targeting: An Emerging Approach for Cancer Therapy

Contact Info

Product

Resources

About